IL17A and colitis: This may partly be because mTORC1 inhibition decreases the expression of IL-23R on CD4+ T cells, a receptor for cytokine (IL-23) that is required for the induction of IL-17A/IFN-γ double-positive T cells and exacerbates the clinical course in murine colitis (Ahern et al. 2010).